search
Back to results

Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds (EMGEL)

Primary Purpose

Local Pain, Chronic Wounds

Status
Terminated
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Morphine gel
Neutral gel
Sponsored by
Institut Curie
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Local Pain focused on measuring topical morphine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, aged over 18 years
  • Painful chronic wounds (bedsores, wound tumor, arterial ulcers, venous or mixed diabetic ulcer if systolic pressure index >0.8, necrotic angiodermatitis not graftable), a bottom surface 300 cm² and does not require more than 15 ml of gel by application. When patient has multiple painful chronic wounds, the wound having only the highest pain intensity is considered for evaluation.
  • Ineffective systemic analgesic with or without opioid analgesic established and maintained at the same dose for 3 days before inclusion. If treatment includes morphine, the daily dose should not exceed 60 mg of morphine equivalent and this treatment must be a treatment exclusive background.
  • Patient requiring an analgesic equilibration for intense and rebellious local pain, with a daily average score greater than or equal to 5, on a graduated numerical scale of 0 to 10. The score is defined at the inclusion and corresponds to the pain intensity felt locally by the patient under treatment systemic analgesic with or without co-analgesics.
  • If analgesics to treat systemic pain is ongoing, it must have been introduced for more than 3 days (according to criteria 3)
  • If antidepressant treatment is in progress, it must have been established for over a month for a tricyclic and for more than 15 days for other classes of antidepressants.
  • If an anti-epileptic treatment analgesic is in progress, it must have been established for over 15 days.
  • Signing of the informed consent form.
  • Patient able to respond the self-assessment questionnaires (sufficient understanding assessments, proficiency in French).
  • Patient affiliated to an health insurance plan

Exclusion Criteria:

  • Allergy to morphine or carboxymethylcellulose or history of intolerance to morphine
  • Analgesic at baseline including systemic morphine to greater than 60 mg equivalent dose of morphine treatment
  • Fistulated wound
  • Heavily exuding wound
  • Wound bleeding (spontaneous bleeding)
  • Ongoing radiotherapy on chronic wound
  • Creatinine > 110 µmol/L, Total bilirubin > 20 µmol/L
  • Not communicating patient
  • Unable to comply with requirement of the protocol (11 days)
  • Patient pregnant or of childbearing age without contraceptive therapy or lactating
  • Person deprived of liberty or under guardianship
  • Only for pharmacokinetic analysis: analgesics at baseline including morphine or hydromorphone or oxycodone or codeine. Fentanyl is allowed

Sites / Locations

  • Hôpital Louis Mourier
  • Institut Curie
  • Hôpital Jean-Jaurès
  • Groupe Hospitalier Bichat
  • Institut Curie - Hôpital René Huguenin

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Morphine gel

Neutral gel

Arm Description

morphine 30 mg, quantity of gel per application: 15mg (15ml)

water for injection, quantity of gel per application: 15mg (15ml)

Outcomes

Primary Outcome Measures

Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg for the last 72 hours of the study
Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg (either up to 3 tablets 10 mg per day) for the last 72 hours of the study (day 8 to day 11) and for which the basic treatment is unchanged throughout the duration of the study

Secondary Outcome Measures

Reduction in average daily pain intensity score on a numerical rating scale self assessment, measured on an 11-point between day 1 and day 11
Reduction in average daily pain intensity score on a numerical rating scale (where 0=no pain and 10=worst possible pain) self assessment, measured on an 11-point between day 1 and day 11. Therefore patients evaluate each morning local pain of the previous 24 hours.
Evaluate the percentage of local pain relief for 24 hours on a rating scale from 0 to 100%
Assess and characterize the evolution of local pain on a global impression scale change : Pain related Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC)
Assess patient satisfaction with treatment of local pain (score 0-4)
Evaluate the impact score of local pain on sleep (self-report scale of 0 to 100%)
0% no impact of pain on sleep 100% maximum impact of pain on sleep, inability to sleep
Determine the time (in hours) before using oral immediate-release morphine after application of local treatment
Determination of cumulative dose of oral immediate-release morphine (in milligrams) of the 11 days of treatment for relieving painful access of local origin
Evaluate systemic and local side effects of analgesic treatment (incidence, severity and location)
Evaluate the systemic absorption of topical morphine blood test after the first application

Full Information

First Posted
January 6, 2014
Last Updated
November 18, 2016
Sponsor
Institut Curie
Collaborators
Assistance Publique - Hôpitaux de Paris, Hôpital Louis Mourier
search

1. Study Identification

Unique Protocol Identification Number
NCT02028923
Brief Title
Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds
Acronym
EMGEL
Official Title
Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Terminated
Why Stopped
Recruiting patients too low
Study Start Date
April 2014 (undefined)
Primary Completion Date
July 2016 (Actual)
Study Completion Date
July 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut Curie
Collaborators
Assistance Publique - Hôpitaux de Paris, Hôpital Louis Mourier

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This phase III study aims to show that topical morphine low doses treats localized pain in chronic wounds, intense and rebellious to systemic analgesics included or not opioids.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Local Pain, Chronic Wounds
Keywords
topical morphine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
126 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Morphine gel
Arm Type
Experimental
Arm Description
morphine 30 mg, quantity of gel per application: 15mg (15ml)
Arm Title
Neutral gel
Arm Type
Placebo Comparator
Arm Description
water for injection, quantity of gel per application: 15mg (15ml)
Intervention Type
Drug
Intervention Name(s)
Morphine gel
Intervention Description
Topical
Intervention Type
Other
Intervention Name(s)
Neutral gel
Intervention Description
Topical
Primary Outcome Measure Information:
Title
Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg for the last 72 hours of the study
Description
Proportion of patients whose maximum daily consumption in immediate-release oral morphine is less than or equal to 30 mg (either up to 3 tablets 10 mg per day) for the last 72 hours of the study (day 8 to day 11) and for which the basic treatment is unchanged throughout the duration of the study
Time Frame
11 days
Secondary Outcome Measure Information:
Title
Reduction in average daily pain intensity score on a numerical rating scale self assessment, measured on an 11-point between day 1 and day 11
Description
Reduction in average daily pain intensity score on a numerical rating scale (where 0=no pain and 10=worst possible pain) self assessment, measured on an 11-point between day 1 and day 11. Therefore patients evaluate each morning local pain of the previous 24 hours.
Time Frame
11 days
Title
Evaluate the percentage of local pain relief for 24 hours on a rating scale from 0 to 100%
Time Frame
11 days
Title
Assess and characterize the evolution of local pain on a global impression scale change : Pain related Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC)
Time Frame
11 days
Title
Assess patient satisfaction with treatment of local pain (score 0-4)
Time Frame
11 days
Title
Evaluate the impact score of local pain on sleep (self-report scale of 0 to 100%)
Description
0% no impact of pain on sleep 100% maximum impact of pain on sleep, inability to sleep
Time Frame
11 days
Title
Determine the time (in hours) before using oral immediate-release morphine after application of local treatment
Time Frame
11 days
Title
Determination of cumulative dose of oral immediate-release morphine (in milligrams) of the 11 days of treatment for relieving painful access of local origin
Time Frame
11 days
Title
Evaluate systemic and local side effects of analgesic treatment (incidence, severity and location)
Time Frame
11 days
Title
Evaluate the systemic absorption of topical morphine blood test after the first application
Time Frame
11 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, aged over 18 years Painful chronic wounds (bedsores, wound tumor, arterial ulcers, venous or mixed diabetic ulcer if systolic pressure index >0.8, necrotic angiodermatitis not graftable), a bottom surface 300 cm² and does not require more than 15 ml of gel by application. When patient has multiple painful chronic wounds, the wound having only the highest pain intensity is considered for evaluation. Ineffective systemic analgesic with or without opioid analgesic established and maintained at the same dose for 3 days before inclusion. If treatment includes morphine, the daily dose should not exceed 60 mg of morphine equivalent and this treatment must be a treatment exclusive background. Patient requiring an analgesic equilibration for intense and rebellious local pain, with a daily average score greater than or equal to 5, on a graduated numerical scale of 0 to 10. The score is defined at the inclusion and corresponds to the pain intensity felt locally by the patient under treatment systemic analgesic with or without co-analgesics. If analgesics to treat systemic pain is ongoing, it must have been introduced for more than 3 days (according to criteria 3) If antidepressant treatment is in progress, it must have been established for over a month for a tricyclic and for more than 15 days for other classes of antidepressants. If an anti-epileptic treatment analgesic is in progress, it must have been established for over 15 days. Signing of the informed consent form. Patient able to respond the self-assessment questionnaires (sufficient understanding assessments, proficiency in French). Patient affiliated to an health insurance plan Exclusion Criteria: Allergy to morphine or carboxymethylcellulose or history of intolerance to morphine Analgesic at baseline including systemic morphine to greater than 60 mg equivalent dose of morphine treatment Fistulated wound Heavily exuding wound Wound bleeding (spontaneous bleeding) Ongoing radiotherapy on chronic wound Creatinine > 110 µmol/L, Total bilirubin > 20 µmol/L Not communicating patient Unable to comply with requirement of the protocol (11 days) Patient pregnant or of childbearing age without contraceptive therapy or lactating Person deprived of liberty or under guardianship Only for pharmacokinetic analysis: analgesics at baseline including morphine or hydromorphone or oxycodone or codeine. Fentanyl is allowed
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Valerie LAURENT, MD
Organizational Affiliation
Institut Curie - Hôpital René Huguenin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Audrey Hurgon, MD
Organizational Affiliation
Institut Curie Paris
Official's Role
Study Director
Facility Information:
Facility Name
Hôpital Louis Mourier
City
Colombes
State/Province
Ile de France
ZIP/Postal Code
92700
Country
France
Facility Name
Institut Curie
City
Paris
State/Province
Ile de France
ZIP/Postal Code
75005
Country
France
Facility Name
Hôpital Jean-Jaurès
City
Paris
State/Province
Ile de France
ZIP/Postal Code
75019
Country
France
Facility Name
Groupe Hospitalier Bichat
City
Paris
State/Province
Ile de France
ZIP/Postal Code
75877
Country
France
Facility Name
Institut Curie - Hôpital René Huguenin
City
Saint-Cloud
State/Province
Ile de France
ZIP/Postal Code
92210
Country
France

12. IPD Sharing Statement

Learn more about this trial

Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds

We'll reach out to this number within 24 hrs